According to the 2022 WHO classification, 12 patients (31.6%) were defined as MDS with low blasts (MDS-LB), 7 patients (18.4%) as MDS with increased blasts-1 (MDS-IB1), 6 patients (15.8%) as MDS with increased blasts-2 (MDS-IB2), 5 patients (13.2%) as MDS with TP53 mutation (TP53-MDS), 3 patients (7.9%) as MDS with del(5q) (MDS-5q), 3 patients (7.9%) as MDS with SF3B1 mutation, and one patient (2.6%) as MDS with fibrosis. This evidence concerns the gene TP53 and myelodysplastic syndrome.